RxDoctor Payments Data

Joseph Lavi, MD

Internal Medicine · Valencia, CANPI 1912082017

Payments from drug & device makers

$10,325in general payments, 2019–2025

Across 403 payments — averaging $25.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • GSK$951
  • AstraZeneca$871
  • Boehringer Ingelheim$735
  • Pfizer$495
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$10,303100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,325 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$93,228
Medicare patients
307
Services billed
910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide203$194,181
JardianceEmpagliflozin132$167,825
EliquisApixaban81$89,003
XareltoRivaroxaban58$60,516
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$49,905
FarxigaDapagliflozin Propanediol30$40,547
ProliaDenosumab18$31,832
MounjaroTirzepatide14$25,818
LinzessLinaclotide23$21,482
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$13,436
EntrestoSacubitril/Valsartan14$10,704
DapagliflozinDapagliflozin Propanediol13$8,167
TradjentaLinagliptin13$6,192
Rosuvastatin Calcium359$5,188
Levothyroxine Sodium357$5,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,360$194,181203 claims
Boehringer IngelheimJardiance, Tradjenta$735$174,017145 claims
PfizerEliquis$495$89,00381 claims
Johnson & JohnsonXarelto$58$60,51658 claims
AstraZenecaFarxiga, Breztri Aerosphere$871$53,98452 claims
GSKTrelegy Ellipta$951$49,90543 claims
AmgenProlia$353$31,83218 claims
Lilly USA, LLCMounjaro$443$25,81814 claims
AbbVieLinzess, Synthroid$1,940$24,64862 claims
NovartisEntresto$104$10,70414 claims
Sanofi-aventis U.S. LLCLantus$125$2,27012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Valencia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →